2021
51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D
HUGHES A, CHAPMAN K, BISPHAM J, HEYDARIAN N, DIMSITS J, WEINZIMER S, WOLF W. 51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D. Diabetes 2021, 70 DOI: 10.2337/db21-51-lb.Peer-Reviewed Original ResearchSevere hypoglycemiaGlucagon useMini-dose glucagonUse of glucagonSevere hypoglycemic eventsEase of administrationOvernight hypoglycemiaGlycemic targetsHypoglycemia unawarenessHypoglycemic eventsPrescription costsSleep disruptorsTreatment decisionsNasal administrationHypoglycemiaDiabetes managementFocus groupsGlucagon actionGlucagon treatmentGlucagonEmotional impactAverage durationT1DPerspectives of peopleSpeakers bureau
2020
Precision Dosing of Rapid-Acting Insulin Matters
Aanstoot HJ, Rodriguez H, Weinzimer S, Vint N, Koeneman L. Precision Dosing of Rapid-Acting Insulin Matters. Diabetes Technology & Therapeutics 2020, 22: 346-351. PMID: 32125891, DOI: 10.1089/dia.2019.0374.Peer-Reviewed Original ResearchConceptsGood glycemic controlGlycemic controlHalf-unit insulin pensInsulin pensDiabetes managementInsulin deliveryStringent glycemic controlInadequate glycemic controlType 2 diabetesType 1 diabetesPrecision of dosingDelivery devicesInsulin delivery devicesInsulin therapyGeriatric patientsHypoglycemic eventsPatient preferencesFlexible dosingPhysical activityDosingLiterature searchPrecision dosingDiabetesInsulinCorrective doses
2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer S, Bonnemaire M, Sawhney S, Stewart J, Wang S, de Cassia Castro R, Garg S. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 471-477. PMID: 31335194, PMCID: PMC6708262, DOI: 10.1089/dia.2019.0157.Peer-Reviewed Original ResearchConceptsSotagliflozin 200Insulin therapyHypoglycemia eventsRate of hypoglycemiaType 1 diabetesLevel 2 hypoglycemiaLower ratesImportant hypoglycemiaHypoglycemia ratesWeek 52Adult patientsGlycemic controlHypoglycemic eventsHypoglycemic rateClinical trialsInsulin treatmentPlaceboSotagliflozinHypoglycemiaType 1Phase 3PatientsTherapyWeeksAdults
2018
Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial
Forlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, Ekhlaspour L, Church MM, Weinzimer SA, Jost E, Marcal T, Andre C, Carria L, Swanson V, Lum JW, Kollman C, Woodall W, Beck RW. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care 2018, 41: dc180771. PMID: 30089663, DOI: 10.2337/dc18-0771.Peer-Reviewed Original ResearchConceptsType 1 diabetesSAP armPredictive low glucose suspendSensor-augmented pump therapyNew insulin delivery systemsRandomized Crossover StudySevere hypoglycemic eventsGlucose concentrationMin/dayMean glucose concentrationLow glucose suspendBasal-IQRebound hyperglycemiaSlim X2Glycemic controlPrimary outcomeCrossover studyMedian timeCrossover trialHypoglycemic eventsPump therapyInsulin delivery systemsPercentage of timeHypoglycemiaDiabetes
2009
The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes
Beck R, Hirsch I, Laffel L, Tamborlane W, Bode B, Buckingham B, Chase P, Clemons R, Fiallo-Scharer R, Fox L, Gilliam L, Huang E, Kollman C, Kowalski A, Lawrence J, Lee J, Mauras N, O'Grady M, Ruedy K, Tansey M, Tsalikian E, Weinzimer S, Wilson D, Wolpert H, Wysocki T, Xing D. The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care 2009, 32: 1378-1383. PMID: 19429875, PMCID: PMC2713649, DOI: 10.2337/dc09-0108.Peer-Reviewed Original ResearchConceptsType 1 diabetesContinuous glucose monitoringSevere hypoglycemic eventsCGM groupControl groupHypoglycemic eventsGlucose monitoringGlucose levelsSignificant treatment group differencesMain study outcomeManagement of adultsTreatment group differencesMin/dayStandard glucose monitoringMean A1CA1c levelsMedian timeOutcome measuresA1CBiochemical hypoglycemiaMost outcomesType 1Hypoglycemia dataStudy outcomesDiabetes